Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where James H. Knepshield is active.

Publication


Featured researches published by James H. Knepshield.


Annals of Internal Medicine | 1971

Goodpasture's Syndrome: Recovery from Severe Pulmonary Hemorrhage After Bilateral Nephrectomy

Andrew Nowakowski; Robert B. Grove; Leroy H. King; Tatiana T. Antonovych; Robert W. Fortner; Martial R. Knieser; Charles B. Carter; James H. Knepshield

Abstract A case of Goodpastures syndrome is presented wherein life-threatening pulmonary hemorrhage, refractory to immunosuppressive drug therapy, rapidly resolved after bilateral nephrectomy. Thi...


Transplantation | 1971

Synergism In Immunosuppression: Iii. Allograft Rejection And Humoeal Antibody Production In Intact And Splenectomized Mice

Michael C. Gelfand; Andrew Nowakowski; Eli A. Friedman; James H. Knepshield

SUMMARY Intact and splenectomized mice were given full thickness skin allografts and tetanus toxoid and then treated with several immunosuppressive agents singly and in combination. Both allograft rejection and humoral antibody production were suppressed in a similar proportion of animals by similar treatment protocols. Splenectomy potentiated depression of the cellular and humoral response in mice treated with one agent. A radiosensitive cell essential to humoral and cellular immunocompetence may have been the common target affected in both types of immunosuppression.


Pediatric Research | 1978

413 HEMOCARBOPERFUSION IN CHILDHOOD HEPATIC COMA

Angel R. Colon; Michael C. Gelfand; Zoe Papadopoulou; P Jose; Stanley Cohan; James H. Knepshield; P McCullough

Fulminant hepatic failure and coma in children has a mortality rate of 60 to 70%. Hemocarboperfusion (HCP) employing an acrylic hydrogel polymer coated charcoal column was used in three children ages 8,11, and 13 years presenting with acute encephalopathy and hepatic failure. Two children were in stage IV hepatic coma and one in stage V Reye syndrome. Following HCP all patients showed significant improvements in deranged serum chemistries. Serum ammonia and amino acid concentrations decreased dramatically. Serial examinations revealed no evidence of hemolysis, thrombocytopenia, or microembolization secondary to HCP. One of three patients survived and had no evidence of cerebral edema. The other two patients developed posturing and pupillary changes suggestive of severe cerebral edema prior to HCP. Continuous intracranial pressure monitoring (employing Richmond screw) in one patient showed > 50mmHg (N:0-10) which transiently diminished with mannitol infusion but failed to respond to HCP. The patients who expired had nearly isoelectric EEGs which showed no improvement following HCP.The patient who responded to HCP and had no evidence of cerebral edema is well without complications after a two year period. It is concluded that for effective HCP in children with hepatic encephalopathy, the therapy should be initiated before the onset of cerebral edema.


Transplantation | 1971

Synergism in immunosuppression. II. Effect of splenectomy on suppression of tetanus antitoxin production induced by methylprednisolone, azathioprine, chlorambucil, and radiation.

Michael C. Gelfand; Eli A. Friedman; James H. Knepshield

SUMMARY An in vivo assay of tetanus antitoxin production in the mouse was utilized to evaluate the effect of splenectomy on treatment with immunosuppressive drugs and/or whole body radiation. Methylprednisolone, azathioprine, chlorambucil, and 100 rads of 60Co radiation were administered as single, double, triple, or quadruple agents to splenectomized and intact mice. For both intact and splenectomized mice, the administration of two agents produced greater immunosuppression than one agent and three agents greater than two agents. Treatment with all four agents resulted in the highest percentage of animals with depressed antibody synthesis. Splenectomy reduced antitoxin production and significantly potentiated the immunosuppressive effect of each agent when administered alone. Splenectomy did not increase significantly the immunosuppressive effect of two, three, or four agents in combination therapy.


Arthritis & Rheumatism | 1972

Therapeutic studies in NZB/W mice. I. Synergy of azathioprine, cyclophosphamide and methylprednisolone in combination

Michael C. Gelfand; Alfred D. Steinberg; Raymond Nagle; James H. Knepshield


JAMA | 1975

Geophagia. A cause of life-threatening hyperkalemia in patients with chronic renal failure.

Michael C. Gelfand; Alfredo Zarate; James H. Knepshield


JAMA | 1981

Hemosiderosis in Hemodialysis Patients

Harold Bregman; Michael C. Gelfand; James F. Winchester; James H. Knepshield


Kidney International | 1976

Treatment of hepatic coma with hemoperfusion through polyacrylamide hydrogel-coated charcoal.

Michael C. Gelfand; James H. Knepshield; Cohan S; Ramirez B; George E. Schreiner


Artificial Organs | 2008

Present and future uses of hemoperfusion with sorbents.

James F. Winchester; Michael C. Gelfand; James H. Knepshield; George E. Schreiner


Kidney International | 1974

Detection of antiplatelet antibody activity in patients with renal cortical necrosis

Michael C. Gelfand; Eli A. Friedman; James H. Knepshield; Simon Karpatkin

Collaboration


Dive into the James H. Knepshield's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Eli A. Friedman

SUNY Downstate Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Angel R. Colon

Georgetown University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge